Individualized Ofatumumab versus Fixed Low‐Dose Rituximab in MuSK‐Antibody‐Positive Myasthenia Gravis: A Multicenter Retrospective Cohort Study. // Clinical Neurology and Neurosurgery. – URL: https://www.sciencedirect.com/science/article/pii/S0303846726003525?dgcid=rss_sd_all
Individualized Ofatumumab versus Fixed Low‐Dose Rituximab in MuSK‐Antibody‐Positive Myasthenia Gravis: A Multicenter Retrospective Cohort Study. Clinical Neurology and Neurosurgery. https://www.sciencedirect.com/science/article/pii/S0303846726003525?dgcid=rss_sd_all
“Individualized Ofatumumab versus Fixed Low‐Dose Rituximab in MuSK‐Antibody‐Positive Myasthenia Gravis: A Multicenter Retrospective Cohort Study.” Clinical Neurology and Neurosurgery.
@article{article41349,
title = {Individualized Ofatumumab versus Fixed Low‐Dose Rituximab in MuSK‐Antibody‐Positive Myasthenia Gravis: A Multicenter Retrospective Cohort Study},
journal = {Clinical Neurology and Neurosurgery},
url = {https://www.sciencedirect.com/science/article/pii/S0303846726003525?dgcid=rss_sd_all}
}